PCDH8 is a novel prognostic biomarker in thyroid cancer and promotes cell proliferation and viability
View abstract on PubMed
Summary
This summary is machine-generated.Protocadherin 8 (PCDH8) is elevated in thyroid cancer (THCA), correlating with poor prognosis and influencing tumor growth. This suggests PCDH8 is a potential therapeutic target for THCA patients.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Protocadherin 8 (PCDH8) is a transmembrane protein involved in cell adhesion and signaling, with a controversial role in cancer.
- Its specific involvement in thyroid cancer (THCA) pathogenesis and prognosis is not well-defined.
Purpose Of The Study
- To investigate the role of PCDH8 in thyroid cancer (THCA) using bioinformatic analysis and experimental validation.
- To explore PCDH8 as a potential prognostic biomarker and therapeutic target in THCA.
Main Methods
- Bioinformatic analysis using R and web tools to assess PCDH8 expression, prognostic value, and immune microenvironment correlation in THCA.
- Experimental validation including immunohistochemistry (IHC) on 98 THCA patient samples, cell culture, MTT, and colony formation assays.
Main Results
- PCDH8 expression was significantly higher in THCA tissues compared to normal tissues.
- Elevated PCDH8 levels were associated with poor prognosis, adverse clinical factors, and increased immune cell/checkpoint infiltration.
- PCDH8 promoted THCA cell viability, proliferation, and drug sensitivity, acting as an independent prognostic factor.
Conclusions
- PCDH8 plays a significant role in THCA tumorigenesis, impacting prognosis, immune infiltration, and diagnosis.
- PCDH8 represents a promising therapeutic target for thyroid cancer.

